

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A23C 9/14	A1	(11) International Publication Number: WO 99/15024 (43) International Publication Date: 1 April 1999 (01.04.99)
<p>(21) International Application Number: PCT/US97/16993</p> <p>(22) International Filing Date: 22 September 1997 (22.09.97)</p> <p>(71) Applicant: SEPRAGEN CORPORATION [US/US]; 30689 Huntwood Avenue, Hayward, CA 94544 (US).</p> <p>(72) Inventors: AHMED, Salah, H.; 4214 Walnut Avenue, Fremont, CA 94538 (US). SAXENA, Vinit; 678 Sylvaner Drive, Pleasanton, CA 94566 (US). MIRANDA, Quirinus; 2097 Jonathan, San Jose, CA 95125 (US).</p> <p>(74) Agents: MACKNIGHT, Kamrin, T. et al.; Medlen & Carroll, LLP, Suite 2200, 220 Montgomery Street, San Francisco, CA 94104 (US).</p>		<p>(81) Designated States: AU, CA, JP, KR, NZ, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: SEQUENTIAL SEPARATION OF WHEY PROTEINS AND FORMULATIONS THEREOF</p> <p>(57) Abstract</p> <p>A method is disclosed for sequential separation of whey proteins using radial-flow chromatography. Different buffer systems adjusted to suitable pH and ionic strength are utilized in the separation process. The method separates at least five different proteins from whey. Infant feeding formulas, and other food formulations are also disclosed incorporating therein in different proportions various proteins separated from the whey.</p>		

62

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

WO 99/15024

PCT/US97/16993

- 1 -

SEQUENTIAL SEPARATION OF WHEY PROTEINS AND FORMULATIONS THEREOF

Field Of The Invention

The present invention is related to the separation of whey proteins, particularly to the sequential separation of whey proteins using chromatography and to food related and pharmaceutical formulations using separated whey proteins.

Background Of The Invention

It is well known that the dry content of cow's milk is about 12.5% of which 3.4% constitute total proteins, 3.5% comprise fat components, 4.7% lactose and 0.9% ash. The protein component consists mainly of casein and whey proteins. Other minor components include non-proteinaceous nitrogen compounds, protease peptones, and other minor enzyme proteins.

In the cheese industry, milk proteins are separated into caseins and whey proteins, mainly by two types of precipitation techniques - rennet precipitation and acid precipitation. In rennet precipitation, rennin is added to warm milk (30 - 35° C). The caseins are precipitated leaving the whey proteins in solution. This type of whey is referred to as sweet whey. Acid precipitation is carried out at the isoelectric point of milk which is 4.7 by using a suitable acid. The whey resulting from acid precipitation is referred to as acid-whey. The choice of the method depends on the desired cheese product.

Whey which is a byproduct of the cheese industry has a high nutritional value because of the many valuable proteins in its composition. However, until recently, a major portion of commercially produced whey was discarded, causing major environmental pollution problems. With the advent of stricter environmental controls and regulations and the availability of more recent techniques like membrane separation including ultrafiltration and reverse

WO 99/15024

PCT/US97/16993

- 2 -

osmosis, whey proteins and other products constituted therefrom have become increasingly important in satisfying the needs of the pharmaceutical, dietetic and food industries. Research efforts with varying degrees of success in the area of the isolation of individual proteins from whey and formulations
5 constituted therefrom abound in the dairy and related industries.

The following patents exemplify the various prior art efforts to isolate individual proteins and other constituents from whey and food and pharmaceutical products derived therefrom.

U. S. Patent No. 5,077,067 issued December 31, 1991, to Philippe A.
10 Thibault discloses a process for the selective and quantitative removal of lactoglobulins from whey proteins.

U.S. Patent No. 5,055,558 issued October 8, 1991 to Emilia Chiancone and Maurizio Gattoni describes a method for the selective extraction of β -lactoglobulin from whey or milk by subunit exchange chromatography.

15 U. S. Patent No. 4,791,193, issued December 13, 1988, to Shigeo Okonogi et al., is directed to a method for the preparation of pure lactoferrin from whey or skim milk.

U. S. Patent No. 4,668,771, issued May 26, 1987, to Hiroshi Kawakami et al., provides a method for the isolation and purification of bovine lactoferrin.

20 U. S. Patent No. 4,997,914 issued March 5, 1991 to Hiroshi Kawakami et al., describes a method for the separation and purification of lactoferrin by adsorption chromatography.

U. S. Patent No. 4,820,348 issued April 11, 1989 to Matti Harju is directed to a chromatographic method for the separation of lactose from milk.

25 U. S. Patent No. 4,446,164 issued May 1, 1984 to Roy A. Brog relates to milk like compositions constituted from sweet whey base with additives like

WO 99/15024

PCT/US97/16993

- 3 -

soluble proteins, edible vegetable oils, non-fat dry milk solids, sugar or synthetic sweeteners included therein.

U. S. Patent No. 5,085,881 issued February 4, 1992, to Hans G. Moeller is describes a process for separating fractions from dried milk or milk products
5 for use as food stuffs or food or pharmaceutical adjuvants.

U. S. Patent No. 5,093,143 issued March 3, 1992 to Horst Behr and Friedrich Manz deals with nutrient compositions which simulate milk and are rich in energy and calcium content but poor in albumin and phosphorus.

U. S. Patent No. 4,202,909 issued May 13, 1980 to Harold T. Pederson,
10 Jr., describes a process for the treatment of whey to produce pure lactose and salt products.

U. S. Patent No. 5,008,376 issued April 16, 1991 to Robin C. Bottomley discloses a process for producing a whey fraction with a high concentration of alpha-lactalbumin by ultrafiltration technology.

15 U. S. Patent No. 3,969,337 issued July 13, 1976 to Karl Lauer et al., discloses a method for the chromatographic fractionation of whey.

As the foregoing patents and other literature articles demonstrate, although different laboratory and commercial processes are available for the separation, removal, concentration, and/or purification of selected whey
20 proteins, these prior art methods result in the destruction or disposal of all but one selected protein from the whey, thereby wasting the other valuable proteins therefrom. None of these prior art methods achieve the separation of various proteins from whey in a single process step. It would be desirable, therefore, to provide a method for the continuous and sequential separation of various
25 proteins from whey in a one or two step separation process.

WO 99/15024

PCT/US97/16993

- 4 -

Accordingly, it is an object of the present invention to provide a separation technique which effects a complete sequential separation of whey proteins in one or two process steps.

Another object of the present invention is to provide a separation
5 technique for the sequential and continuous separation of whey proteins which is suitable for laboratory as well as commercial applications using radial flow chromatography technology.

Yet another object is to provide different buffers which are mild enough to use in sequentially separating whey proteins without denaturing them.

10 Still another object is to provide a separation technique applicable for food and pharmaceutical uses of whey proteins.

Another object of the invention is to provide dietary and pharmaceutical formulations comprising various separated whey proteins in differing proportions.

15 Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows and in part will become apparent to those skilled in the art upon examination of the following or may be learned by practice of the invention. The objects and advantages of the invention may be realized and attained by means of the instrumentalities and
20 combinations particularly pointed out in the appended claims.

Summary Of The Invention

To achieve the foregoing and other objectives and in accordance with the purpose and principles of the invention as set forth herein, the present invention basically provides a process for the sequential separation of at least
25 five different proteins from whey and incorporating these separated whey proteins into pharmaceutical and food formulations. The process of the invention is directed to the continuous, sequential separation of whey proteins

WO 99/15024

PCT/US97/16993

- 5 -

by chromatography, comprising adsorbing the proteins in liquid whey on a suitable separation medium packed in a chromatographic column and sequentially eluting IgG, β -Lg, α -La, BSA and lactoferrin fractions with buffers at suitable pH and ionic strength. Even though both axial and radial flow chromatography may be utilized, a horizontal flow column is particularly suitable for the process of this invention. The whey proteins separated by the process of the invention include β -lactoglobulin (β -Lg), α -lactalbumin (α -La), bovine serum albumin (BSA), immunoglobulin (Ig-G) and Lactoferrin (L-Fe). The various formulations of the invention for dietary or pharmaceutical applications incorporate these separated proteins in various proportions.

Brief Description Of The Drawings

Figure 1 is a graphic representation of the elution pattern of the various proteins in accordance with this invention.

Figure 2 presents an elution profile of separated proteins vs. time.

Figure 3 represents the elution pattern and the location of peak 4.

Detailed Description Of The Invention

According to the process of the invention, a sample of a starting material selected from pasteurized sweet whey, pasteurized acid whey, non-pasteurized acid whey obtained as a by-product of cheese manufacture, or whey protein concentrate, prepared from the pasteurized or non-pasteurized whey by known techniques such as reverse osmosis (RO) or ultrafiltration (UF) is loaded on to a chromatographic column, preferably a horizontal flow chromatographic column, packed with either an acidic or basic, cationic or anionic resin material such as macro-prep high S or Q. The whey, concentrated whey or whey protein concentrate may be subjected to pre-separation procedures such as de-ashing through electrodialysis or ion exchange, clarification to remove casein fines,

WO 99/15024

PCT/US97/16993

- 6 -

and /or microfiltration for separating colloidal and suspended particles including fat residues.

The various whey components were then eluted and separated according to the protocols described in the following examples.

5 **Example 1 - Sequential Separation Of Sweet Whey Proteins:**

Commercial whey, a by-product of mozzarella cheese manufacture, was initially clarified to remove casein fines, centrifuged to remove milk fat residue, pasteurized at 162°F for about 18 seconds, and chilled to 40°F by passing it through HTST plate heat exchangers. 1000 ml of this skimmed commercial sweet whey at pH 6.4 and 6.2% total solids, was pH adjusted to 3.8 with acetic acid at 40°F. The composition of this whey product used in this experimental example is presented in Table I.

Table I

WHEY

15	<u>Components</u>	<u>Percentage</u>	
			<u>Protein Composition</u>
	Total solids	6.2	
	Lactose	4.5	β -lactoglobulin 0.29%
	Protein	0.8	α -lactalbumin 0.13%
	Fat	0.08	Serum casein 0.21%
20	Ash	0.77	Immunoglobulin 0.06%
	Lactic Acid	0.05	Lipoprotein 0.06%
			Bovine serum albumin 0.03%
25			Lactoferrin 0.02%

The whey was then passed through a 250 ml radial flow chromatographic column prepacked with a strong S cation exchange resin and equilibrated with 0.05 M acetate buffer at pH 3.8. All the whey proteins were

WO 99/15024

PCT/US97/16993

- 7 -

bound to the resin matrix, and the effluent containing non-protein components including lactose, minerals, lactic acid, and non-protein nitrogenous components is allowed to pass through. The resin with the bound proteins was then washed with 0.05 M acetate buffer at pH 3.8 to a preset UV baseline. The
5 various bound proteins were then sequentially eluted in accordance with the following protocol:

Immunoglobulin (IgG) and β -lactoglobulin (β -Lg) were eluted in sequential order with a buffer at pH 4.0 containing 0.1 M sodium acetate and 0.5 M sodium chloride.

10 The column was then reconditioned and equilibrated with 0.05 M sodium acetate buffer at pH 4.0, to bring the conductivity back to the base line.

α -Lactalbumin (α -La) fraction was eluted with a pH 5.0 buffer containing 0.1 M sodium acetate and 0.1 M sodium chloride. The column was again reconditioned with a pH 5.0 buffer containing 0.05 M sodium acetate to bring
15 the conductivity back to the initially established base line. Bovine serum albumin (BSA) was then eluted with a 0.05 M phosphate buffer at pH 7.0. Thereafter, lactoferrin (LF) was eluted at pH 7.5 with a buffer containing 0.05 M sodium phosphate and 0.5 M sodium chloride.

The column was again regenerated by washing it with a solution
20 containing 0.2 M sodium hydroxide and 1 M sodium chloride, followed by a wash with a 20% ethanol (EtOH) solution to sterilize the column and equilibrated with acetate buffer at pH 3.8 for reuse.


A flow diagram showing the elution protocol is presented in Table II below.

WO 99/15024

PCT/US97/16993

- 8 -

Table II

Flow Diagram Of Elution Protocol

WO 99/15024

PCT/US97/16993

- 9 -

Fractions of each of the eluted proteins were collected in terms of elution "peaks" for further separation, concentration, and other treatment protocols. The elution sequence with the different protein peaks in terms of their UV absorption at 280 nm is presented in Figure 1. Protein identification of each peak was monitored by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), as known in the art. Protein recovery as monitored by bio-rad and gel scan assays at various stages of the elution scheme is presented in Tables III and IV.

Table III

Summary of Bio-Rad Assay Data

(#0)	Column Load 1.0L treated whey 4.3 mg/ml total protein	4.3 g loaded
(#1)	Column Flow-Through 1.65L 0.2 mg/ml total protein	0.3 g (7%)
(#2)	β -Lg + IgG Fraction 2.4L 1.2 mg/ml total protein	2.9 g (67%)
(#3)	α -La Fraction 1.25L 0.5 mg/ml total protein	0.6 g (14%)
(#4)	BSA Fraction 1.625L 0.3 mg/ml total protein	0.4 g (9%)
(#5)	L-Fe Fraction 0.625L 0.09 mg/ml total protein	0.05 g (1%)
(#6)	Wash 1 1.6L 0.03 mg/ml total protein	0.05 g (1%)
(#7)	Wash 2 0.4L 0.09 mg/ml total protein	0.04 g (1%)
Total Recovery = 4.3 g = 100% accountability		

WO 99/15024

PCT/US97/16993

- 10 -

Table IV
Summary Of Gel Scan Data

Gel #1				R2=0.98
Column Load		1.0L treated whey		
		4.5 mg/ml total protein		4.5 g loaded
Approximate % Composition				
		76% β -Lg		
		17% α -La		
		2% BSA		No protein eluted in flow-through
		3% IgG		
		2% Other		

Gel #2		R2=0.99	
Volume = 2.4L		β -Lg and IgG Fraction	
		1.2 mg/ml total protein	2.9 g recovered (64%)
		94% β -Lg	
		2% IgG	

Gel #3		R3=0.993	
Volume = 1.25L		α -La Fraction	
		0.03 mg/ml total protein	0.4 g recovered (9%)
		94% α -La	

Gel #4		R3=0.991	
Volume = 1.625L		BSA Fraction	0.625L L-Fe Fraction
		0.08 mg/ml total protein in BSA Fraction	0.13 g (3%)
		62% BSA recovery (minimum)	
		0.05 mg/ml total protein in L-Fe Fraction	0.03 g (1%)
		45% L-Fe recovery (minimum)	

Example 2 - An Alternative Protocol For Elution Of Whey Proteins

A 20 liter RFC column was packed with a macro-prep 50 S resin. The column was then conditioned, equilibrated, loaded, eluted and reconditioned in exactly the same manner as described in Example 1 above, except that the flow

WO 99/15024

PCT/US97/16993

- 11 -

rates, volume of whey loaded on to the column, flow rates and buffer volumes were varied. Protein elution peaks were monitored at 280 nm using a uv spectrophotometer. A graphical trace of the eluted proteins with their relative concentrations is presented in Figure 2. The proteins eluted with their
 5 respective percentages of purity are shown in Tables V and VI.

Table VProtein Yields In Eluate Fractions

(20 L column; Flow Rate 8L/min; Whey Load 80L)

	<u>Protein</u> (g/L)	<u>Volume</u> (L)	<u>Protein Yield</u> Load (g)	<u>%</u>
Whey Load	8.8	80	704	-
Flow Through (P-1)	0.9	97	87	12
β -La + IgG (P-2)	2.8	89	249	35
α -Lactalbumin (P-3)	1.1	94	103	15
BSA (P-4)	1.1	102	112	16
Lactoferrin (P-5)	0.9	45	41	6
Rinse (P-6)	0.8	22	18	3
Stripping Solution (P-7)	1.2	29	35	5

Protein Recovery: 84%; Protein Accountability: 92%

Table VI

<u>Protein Purity</u> (Gel Scan)	<u>%</u>
β -Lactoglobulin	82
Immunoglobulin	11
α -Lactalbumin	84
Bovine Serum Albumin	59
Lactoferrin	52

WO 99/15024

PCT/US97/16993

- 12 -

Example 3 - Preparation Of An Anionic Exchange Resin Column

A 250 ml RFC column was packed with a strong base, anionic exchange resin - macro-prep 50 Q - and conditioned with 0.2M NaOH + 1 M NaCl at a flow rate of 100 ml/min for 10 minutes. The column was then equilibrated with 0.01M sodium phosphate at pH 6.90 at a flow rate of 100 ml/min for 10 minutes. This column was then used to separate immunoglobulins (IgG) from β -Lactoglobulin eluted as overlapping peaks from Examples 1 and 2 above. This mixture may be incorporated into dietary formulations or used for further separation of the two protein components.

Example 4 - Separation Of Immunoglobulins (IgG) from β -Lactoglobulin

The eluate represented by peak 2, collected from the fractionated material from the process described in Example 1, and containing IgG and β -Lg at pH 4.0, was passed through a 10,000 molecular weight cut-off UF membranes for concentrating the proteins and for reducing the buffer salt concentration and thereby, the ionic strength of the solution. The proteins were further concentrated to 5x their initial eluted concentrations and buffer salt concentrations were reduced to about one-fourth their eluting concentration by diafiltration with distilled water. The diafiltered and concentrated protein solution was pH adjusted to 6.9 with a 2.0M solution of NaOH. Two liters of this protein solution at pH 6.9 was loaded on to the pre-conditioned RFC column as described in Example 3, at a flow rate of 100ml/min. The column was washed with 0.01M sodium phosphate buffer at pH 6.9 to establish a UV baseline. IgG which did not bind to the resin passed through the column with the wash and was collected for further processing. The adsorbed β -Lg was then eluted from the column with 0.05M sodium citrate buffer at pH 3.0 and collected. The column was rinsed with distilled water, stripped of residual proteins with 0.2M

WO 99/15024

PCT/US97/16993

- 13 -

NaOH + 1M NaCl solution, followed by 20% EtOH and again reequilibrated with sodium phosphate buffer at pH 6.9, in preparation for the next cycle.

Example 5 - Separation And Isolation Of BSA

The eluate represented by peak 4, collected from the fractionated
5 material from the process described in Example 1, and containing BSA, and
protease peptone at pH 7.0 was concentrated and diafiltered as described in
Example 4, then pH adjusted to 5.5 with acetic acid. A 250 ml RFC column
prepared as described in Example 4 was rinsed with distilled water at a flow
rate of 100 ml/min. Two liters of the protein solution were loaded onto the
10 column as described earlier. The column was again flushed with distilled water
at a flow rate of 100 ml/min to elute the nonadsorbed protease peptone and to
establish a stable UV baseline. The eluate containing the protease peptone
was collected for further use. The adsorbed BSA was thereafter eluted with
sodium phosphate buffer containing 0.2M sodium chloride at pH 7.0. Figure 3
15 represents the elution pattern and the location of peak 4.

Example 6 - Elution And Separation Of β -Lactoglobulin From Liquid Whey

A 250 ml radial-flow chromatographic column packed with a strong base
20 anionic exchange resin (macro-prep 50 Q) was washed and regenerated
according to manufacturer's instructions. The column was then equilibrated
with 0.05M sodium phosphate (tribasic) at pH 7.5 at a flow rate of 100 ml/min for
10 min. pH ranges of 7.0 to 8.0 did not significantly affect the elution pattern.
Two liters of clarified, skimmed, pasteurized sweet whey from mozzarella
25 cheese manufacture, chilled to 40°F were pH adjusted to 8.0 with 5M sodium
hydroxide, were circulated through the pre-prepared column at 75 ml/min for
equilibration. Flow rates in the range of 50-100 ml/min may be utilized. Then a
1 to 3 liter sample of whey to be analyzed was loaded on to the column and the

WO 99/15024

PCT/US97/16993

- 14 -

column eluted with the loading buffer - 0.05 M sodium phosphate at pH 7.5. Under the conditions utilized, all whey proteins except β -lactoglobulin are positively charged. β -lactoglobulin being negatively charged, is bound to and retained by the anionic exchange resin. The effluent containing non-bound
5 proteins [α -Lactalbumin (α -La), Immunoglobulin (Ig-G), bovine serum albumin (BSA) and lactoferrin (L-Fe)] was allowed to pass through the column, collected and stored at 40°F for further processing.

The adsorbed β -lactoglobulin was then eluted from the column with a pH 7.5 buffer containing 0.05 M sodium phosphate and 0.5 M sodium chloride.
10 This eluate containing β -lactoglobulin may be processed further to prepare a shelf stable product in the same manner as described in Example 8 below.

The column was washed with 1M sodium chloride at a flow rate of 125 ml/min for about four column volumes (2 liters), stripped with 1 M sodium hydroxide at the same flow rate, regenerated with 1 M sodium chloride at a flow
15 rate of 100 ml/min for about five column volumes (2 1/2 liters) sanitized with 200 ppm sodium hypochlorite at 100 ml/min for about four column volumes (2 liters) and then equilibrated with the loading buffer in preparation for the next cycle.

20 **Example 7 - Elution And Sequential Separation Of Four Proteins From A Non- β -Lactoglobulin Fraction Of Liquid Whey**

The flow-through fraction from Example 6, containing 0.55% protein, was passed through a 10000 molecular weight cut-off, spiral ultra-filtration membrane to a 35% of the original volume, removed as a permeate for the purpose of partial protein concentration and also for reduction of soluble salts.
25 This pre-treatment procedure facilitates the optimum absorption and sequential desorption of Ig-G, α -La, BSA and L-Fe protein fractions as outlined in Example 1. The prepared flow-through was pH adjusted to 3.8 with acetic acid and 1500 ml sample of it was loaded onto a 250 ml RFC column packed with a strong S-cationic exchange resin and pre-equilibrated with 0.05 M sodium acetate buffer


WO 99/15024

PCT/US97/16993

- 15 -

at pH 3.8. Washing, sequential elution and regeneration steps as outlined in Example 1 were followed. The eluted protein fractions were individually passed through the appropriate molecular weight cut-off - 50000 MW cut-off membrane for Ig-G, L-Fe and BSA and 10000 MW cut-off membrane for α -La - to concentrate proteins and eliminate salt residues. It was then processed further to a finished product as outlined in Example 8.

Example 8 - Flow Diagram Showing Preparation Of Final Product



The whey protein fractions or the separated and purified proteins and the non-proteinaceous eluants may be incorporated into dietary and pharmaceutical formulations in appropriate proportions. Such formulations include but are not limited to infant formulas, fat substitutes, foaming agents, egg white substitutes, animal feed substitutes and the like.

WO 99/15024

PCT/US97/16993

- 16 -

Example 9 - Infant Formulas

In the infant formulas constituted in accordance with this invention, the casein and whey fractions of cow's milk were modified to achieve a composition simulating human milk to a significantly larger degree than prior art compositions and commercial products. The infant formulas of the present invention contain whey proteins at levels similar to those in human milk. This was achieved by producing a whey protein ingredient mix containing the type and ratio of whey proteins of human milk.

Commercially available infant formulas are constituted from whole cow's milk, mostly because of its availability on a large scale. Other additives or adjuvants may be included. These formulas are manufactured either in powder, concentrated or ready to feed preparation. They consist, for the most part, of non-fat milk solids, vegetable oils and carbohydrate sweeteners such as lactose, corn syrup solids and sucrose. These formulas may also be fortified with vitamin C, vitamin D, iron and fluoride. Table VII shows the typical compositions of a few exemplary commercial infant formulas in comparison to one exemplary formula of the present invention. Levels of vitamins, minerals and other fortifiers in the formulation of the present invention are adjusted to simulate human milk and to meet nutritional requirements of infants.

WO 99/15024

PCT/US97/16993

- 17 -

Table VII

Composition Range Of Some Commercial Infant Formulas Compared To
One Exemplary Formulation Of The Present Invention

Nutrients	Commercial Infant Formulas (Similac, Alimentum, Good Start, Gerber etc.)	Formula Of Present Invention		
	Per 5 Oz Prepared Feed (~12.5 % solids)	Ingredients	Per 5 oz Prepared Feed (~12.5 % solids)	Ingredients
Protein	2.14 - 2.75 g	NFDM* - Casein hydrolysate - whey protein composition	1.1 - 2.50 g	Dry or wet mix of purified, selected proteins
Fat	5.1 - 5.54 g	veg, coconut, soy, palm, safflower, sun flower oil etc.	4.30 - 6.48 g	veg oils, milk fat
Carbo- hydrate	10.2 - 11.0 g	lactose, sucrose	10.19 - 10.50 g	lactose
Water	133 - 135 g		15 - 130 g	
Linoleic Acid	850 - 1600 mg		1200 - 1300 mg	
Vit. A	300 IU		300 - 350 IU	
Vit. D	45 - 60 IU		50 - 60 IU	
Vit. E	2.0 - 3.0 IU		2.2 - 2.7 IU	
Vit. C	9 mg		7 - 9 mg	
Vit. K	8 - 15 mcg		8 - 10 mcg	
Vit. B1	60 - 100 mcg		25 - 100 mcg	
Vit. B2	90 - 150 mcg		50 - 150 mcg	
Vit. B6	60 - 75 mcg		20 - 60 mcg	
Vit. B12	0.22 - 0.45 mcg		0.10 - 0.25 mcg	
Niacin	750 - 1350 mcg		300 - 1100 mcg	
Folic Acid	9 - 15 mcg		7 - 15 mcg	
Pantothenic Acid	450 - 750 mcg		330 - 450 mcg	
Biotin	2.2 - 4.5 mcg		2 - 4 mcg	
Choline	8 - 16 mg		10 - 16 mg	
Inositol	4.7 - 18 mg		4.5 - 5.5 mg	
Calcium	64 - 105 mg		47 - 73 mg	
Phosphorus	36 - 75 mg		21 - 56 mg	
Magnesium	6.0 - 7.5 mg		4.4 - 6.0 mg	
Iron	0.5 - 1.8 mg		0.04 - 1.8 mg	
Zinc	0.75 mg		0.25 - 0.75 mg	
Manganese	5 - 30 mcg		5 - 10 mcg	
Copper	75 - 90 mcg		75 - 90 mcg	
Iodine	8 - 15 mcg		9 - 12 mcg	
Sodium	24 - 44 mg		25 - 40 mg	
Potassium	98 - 118 mg		75 - 110 mg	
Chloride	59 - 80 mg		59 - 80 mg	
Cholesterol	-		18 - 25 mg	

* NFDM - non-fat dry milk solids

WO 99/15024

PCT/US97/16993

- 18-

However, due to the large differences in the protein compositions of cow's milk and human milk, some infants show different degrees of intolerance to cow's milk and food formulas constituted therefrom. A comparison of the composition of cow's milk with that of human milk is presented in Table VIII and a comparison of their protein content is presented in Table IX.

Table VIII

Comparison of Cow's Milk With Human Milk

<u>Per 100g</u>	<u>Cow</u>	<u>Human</u>
Water g.	89.99	87.5
Food Energy kcal.	61	70
Protein (N x 6.38) g.	3.29	1.03
Fat g.	3.34	4.38
Carbohydrate (total) g.	4.66	6.89
Fiber g.	0	0
Ash g.	0.72	0.2
Minerals		
Calcium mg.	119	32
Iron mg.	0.05	0.03
Magnesium mg.	13	3
Phosphorus mg.	93	14
Potassium mg.	152	51
Sodium mg.	49	17
Zinc mg.	0.38	0.17
Vitamins		
Ascorbic Acid mg.	0.94	5.00
Thiamin mg.	0.038	0.014
Riboflavin mg.	0.162	0.036
Niacin mg.	0.084	0.177
Pantothenic Acid mg.	0.314	0.223
Vitamin B6 mcg.	0.042	0.011
Folic Acid mcg.	5	5
Vitamin B12 mcg.	0.357	0.045
Vitamin A I.U.	126	241
Cholesterol mg.	14	14

WO 99/15024

PCT/US97/16993

- 19 -

Table IXProtein Composition Of (Cow & Human Milk) g/100g

<u>Protein</u>	<u>Cow</u>	<u>Human</u>
Casein (total)	2.6	0.32
β -Lactoglobulin	0.32	Negligible
α -Lactalbumin	0.12	0.28
Serum albumin	0.04	0.06
Lysozyme	Negligible	0.04
Lactoferrins	0.02	0.20
Immunoglobulins	0.07	0.10

A ratio of the various whey proteins between cow's and human milk is presented in Table X.

Table XRatio Of Various Whey proteins in Cow's & Human Milk

<u>Protein</u>	<u>Cow's Milk (g/100g)</u>	<u>%(1)</u>	<u>Human Milk</u>	<u>%</u>	<u>Ratio H/C (2)</u>	<u>1x2</u>	<u>Mix Composition</u>
α -La	0.12	48	0.28	43.75	2.33	1.10	43.5
L-Fe	0.02	8	0.20	31.25	10	0.80	31.6
IgG	0.07	28	0.10	15.63	1.43	0.39	15.4
BSA	0.04	16	0.06	9.37	1.5	0.24	9.5

As shown in the foregoing tables, cow's milk contains 3.3% protein while human milk has only 1%. Caseins are the major protein components in cow's milk (about 77% of total protein) whereas human milk contains a high ratio of whey proteins to caseins (about 2:1). β -Lactoglobulin concentration in cow's milk is the highest of the whey proteins while it is negligible in human milk. similarly, lactoferrin is ten times higher in concentration in human milk than in

WO 99/15024

PCT/US97/16993

- 20 -

cow's milk. Immunoglobulin and serum albumin concentrations are about 1.5 times higher in human milk than in cow's milk.

In the infant formula of the present invention, lactose and fat levels are adjusted to simulate human milk. Vegetable fat replaces butter fat. Casein to whey ratio is also reduced to simulate human milk. Other additives and supplements such as vitamins, taurine, and minerals may be included if desired. The total solute load is reduced to the level found in human milk.

To achieve this objective, whey protein fractions obtained from the fractionation and elution in accordance with the process of this invention, were first combined in the ratio shown in Table XI below.

Table XIDietary Formulation A

α -Lactalbumin fraction	43.5%
Lactoferrin fraction	31.6%
Immunoglobulin fraction	15.4%
Bovine serum albumin fraction	9.5%

The above whey protein mix was then incorporated into a human milk-like formulation with the composition shown in Table XII.

Table XII

<u>Ingredient</u>		<u>Infant Formula</u> <u>Liquid formula (g/100g)</u>	<u>Dry Formula Base (g/6oz liquid)</u>
Water		87.20	
β -Casein		0.28	0
κ -Casein		0.04	0.504
			0.072
Prepared whey protein mix	<div> <div> α-La BSA L-Fe IgG </div> <div>→ 0.64</div> </div>		1.152
Lysozyme	0.04		
Lactoperoxidase	750 (activity)		0.072
Fat	4.5		1350
Lactose	7.0		8.1
Ash	0.2		12.6
			0.36

WO 99/15024

PCT/US97/16993

- 21 -

The liquid mix prepared according to the above composition contained about 2% total solids, (of which salts from the eluting buffers comprise 90% and total proteins comprise about 10%), and 98% water. This liquid mix was then concentrated through a 10,000 molecular weight cut-off, spiral ultrafiltration
5 membrane to 5-15% total proteins, followed by diafiltration with distilled water at 0.5-1.0x to remove remaining salt residues. This formulation may be further concentrated by processes normally utilized in the treatment of labile proteins, such as ultrafiltration, reverse osmosis, freeze drying, freeze concentration, spray drying and the like or any combination thereof. The formulations of this
10 invention may be further fortified with suitable additives and fortifiers. Such additives and fortifiers include but are not limited to nonfat milk solids, vegetable solids, carbohydrate sweeteners, minerals and vitamins. The solid composition of one exemplary formulation of the present invention is presented in Table XIII.

WO 99/15024

PCT/US97/16993

- 22 -

Table XIII

Solid Composition Of One Exemplary Formulation Of The Present Invention

<u>Ingredients</u>	<u>gm / 16 oz of Formula Powder</u>
<u>Proteins:</u>	
Casein Hydrolysate	11.00
α -Lactalbumin	9.63
Bovine Serum Albumin	2.06
Lactoferrin	6.88
Immunoglobulins	3.44
Lysozyme	1.38
<u>Fat</u>	
Coconut Oil	53.56
Sunflower Oil	46.08
Corn Oil	36.79
Butter Fat	14.10
<u>Carbohydrate:</u>	
Lactose	236.95
<u>Moisture (Water Content):</u>	
<u>Linoleic Acid:</u>	15.20
<u>Vitmins:</u>	2.41
Vit. A	
Vit. D	8288 (IU)
Vit. E (tocopherol)	1720 (IU)
Vit. K	86 (IU)
Vit. B1	0.0003
Vit. B2	0.0018
Vit. B6	0.0012
Vit. B12	0.0004
Vit. C (ascorbic acid)	0.0000002
Niacin	0.17
Folic Acid	0.006
Pantothenic Acid	0.0001
Biotin	0.008
Choline	0.0001
Inositol	0.34
<u>Minerals:</u>	0.18
Calcium	
Phosphorus	1.10
Magnesium	0.48
Iron	0.10
Zinc	0.001
Manganese	0.006
Copper	0.0003
Iodine	0.003
Sodium	0.0003
Potassium	0.59
Chloride	1.76
Cholesterol	2.06
	0.48

WO 99/15024

PCT/US97/16993

- 23 -

Example 10 - Formulations As Fat Substitutes

β -lactoglobulin exhibits high water-binding qualities and α -lactalbumin increases viscosity and also absorbs a high content of fats and oils. because of these properties, a combination of these proteins would lend itself to use as fat substitutes. This product when incorporated in appropriate proportions into some food products improves the quality and characteristics of the product and may be used as a fat substitute.

β -lactoglobulin elutes, and along with IgG, as fraction 2 in the process of the present invention and α -lactalbumin is eluted in fraction 3. IgG is separated from the β -lactoglobulin fraction as described in Example 7 and is mixed with the α -lactalbumin fraction in a 60 and 40% ratio. The mix of the two proteins (β -La + α -La) is passed through a 10,000 molecular weight cut-off ultra-filtration membrane at 40°F with a differential pressure of 10 psi and the permeate, consisting of water and soluble salts, is removed until a 40-50% total solids concentration is achieved. This is followed by a diafiltration at 0.5x with distilled water to remove remaining salt residues. The concentrated and purified mix thus obtained may be frozen, freeze-dried, chilled or dehydrated for further use. Other additives such as flavor enhancers, vitamins and sweeteners may be included in these formulations as desired.

It has thus been shown that the present invention provides a method for the continuous and sequential separation of whey proteins and formulation of the eluted fractions which may be used as food additives or substitutes.

The foregoing description of the preferred embodiments of the subject invention have been presented for purposes of illustration and description and for a better understanding of the invention. It is not intended to be exhaustive or to limit the invention to the precise form disclosed; and, obviously, many modifications and variations are possible in the light of the above teaching. The

WO 99/15024

PCT/US97/16993

- 24 -

particular embodiments were chosen and described in some detail to best explain the principles of the invention and its practical application thereby to enable others skilled in the relevant art to best utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated. It is intended that the invention be defined by the claims
5 appended hereto.

WO 99/15024

PCT/US97/16993

- 25 -

CLAIMS

1. A method for the continuous sequential separation of whey proteins by chromatography, comprising adsorbing liquid whey on a separation medium packed in a chromatographic column, and sequentially eluting immunoglobulin, β -lactoglobulin, α -lactalbumin, bovine serum albumin, and lactoferrin fractions.
2. The method of Claim 1, wherein said liquid whey is selected from the group consisting of pasteurized sweet whey, pasteurized acid whey, non-pasteurized acid whey, and whey protein concentrate.
3. The method of Claim 1, wherein said separation medium is a cationic resin.
4. The method of Claim 1, wherein said sequentially eluted immunoglobulin, β -lactoglobulin, α -lactalbumin, bovine serum albumin, and lactoferrin fractions are collected and concentrated by ultrafiltration.
5. The method of Claim 4, wherein said concentrated immunoglobulin, β -lactoglobulin, α -lactalbumin, bovine serum albumin, and lactoferrin fractions are further purified by diafiltration.
6. A method for the sequential separation of whey proteins, comprising the steps of:
 - a) packing a chromatographic column with a cationic exchange resin to provide a packed chromatographic column;
 - b) equilibrating said packed chromatographic column;
 - c) providing a whey sample;
 - d) passing said whey sample through said packed chromatographic column, under conditions whereby said whey proteins adsorb to said packed chromatographic column;
 - e) collecting the flow-through from said packed chromatographic column, wherein said flow-through comprises lactose, minerals, lactic acid, and non-nitrogenous components;

WO 99/15024

PCT/US97/16993

- 26 -

- f) sequentially eluting immunoglobulin and β -lactoglobulin from said packed chromatographic column;
 - g) eluting α -lactalbumin from said packed chromatographic column;
 - h) reconditioning said packed chromatographic column;
 - i) eluting bovine serum albumin from said packed chromatographic column; and
 - j) eluting lactoferrin from said packed chromatographic column.
7. The method of Claim 6, wherein said whey is selected from the group consisting of pasteurized sweet whey, pasteurized acid whey, non-pasteurized acid whey, and whey protein concentrate.
8. The method of Claim 6, wherein said chromatographic column is a radial flow column.
9. A method for the separation of β -lactoglobulin from whey proteins, said process comprising the steps of:
- a) packing a chromatographic column with an anionic exchange resin to provide a first packed chromatographic column;
 - b) equilibrating said first packed chromatographic column;
 - c) providing a whey sample;
 - d) passing said whey sample through said first packed chromatographic column under conditions wherein β -lactoglobulin adsorbs to said first packed chromatographic column;
 - e) collecting the flow-through from said first packed chromatographic column, wherein said flow-through comprises α -lactalbumin, immunoglobulin, bovine serum albumin and lactoferrin suitable for further processing; and
 - f) eluting said adsorbed β -lactoglobulin from said first packed chromatographic column with a buffer to produce an eluate.
10. The method of Claim 9, wherein said first packed chromatographic column is a radial flow column.

WO 99/15024

PCT/US97/16993

- 27 -

11. The method of Claim 9, further comprising the steps of:
 - g) packing a second chromatographic column with an cationic exchange resin to provide a second packed chromatographic column;
 - h) equilibrating said second packed chromatographic column;
 - i) passing said flow-through through a 10,000 molecular weight cut-off ultrafiltration membrane to produce an ultrafiltrate;
 - j) passing said ultrafiltrate through said second packed chromatographic column, under conditions such that immunoglobulin, α -lactalbumin, bovine serum albumin, and lactoferrin adsorb to said second packed chromatographic column;
 - k) eluting said immunoglobulin from said second packed chromatographic column;
 - l) eluting said α -lactalbumin from said second packed chromatographic column;
 - m) reconditioning said second packed chromatographic column;
 - n) eluting said bovine serum albumin from said second packed chromatographic column; and
 - o) eluting said lactoferrin from said second packed chromatographic column.
12. The method of Claim 11, wherein said second packed chromatographic column is radial flow column.
13. The method of Claim 12, wherein said flow-through comprises an infant formula.
14. The method of Claim 13, wherein said infant formula contains at least 25% lactoferrin and less than one half of a percent of β -lactoglobulin.
15. The method of Claim 13, wherein said infant formula comprises about 43.5% α -lactalbumin, about 31.6% lactoferrin, about 15.4% immunoglobulin, and about 9.5% bovine serum albumin.

WO 99/15024

PCT/US97/16993

- 28 -

16. The method of Claim 14, wherein said infant formula further comprises casein hydrolysate, fat, nonfat milk solids, carbohydrate, minerals, and vitamins.

17. The method of Claim 13, wherein said flow-through is combined with said eluate to produce a fat substitute.

18. The method of Claim 17, wherein said fat substitute comprises about 60% β -lactoglobulin and 40% α -lactalbumin.

19. A method for the sequential separation of whey proteins, comprising the steps of:

- a) packing a chromatographic column with a cationic exchange resin to provide a packed chromatographic column;
- b) equilibrating said packed chromatographic column with a buffer;
- c) providing a whey sample containing whey proteins comprising lactoferrin, immunoglobulin, β -lactoglobulin, α -lactalbumin, and bovine serum albumin;
- d) passing said whey sample through said packed chromatographic column, under conditions whereby at least a portion of said whey proteins adsorb to said packed chromatographic column;
- e) washing said packed chromatographic column with a buffer;
- f) sequentially eluting immunoglobulin and β -lactoglobulin from said packed chromatographic column with a buffer;
- g) reconditioning said packed chromatographic column;
- h) eluting α -lactalbumin from said packed chromatographic column with a buffer;
- i) reconditioning said packed chromatographic column with a buffer;
- j) eluting bovine serum albumin from said packed chromatographic column with a buffer; and
- k) eluting lactoferrin from said packed chromatographic column with a buffer to create an eluate containing lactoferrin.

20. The method of Claim 19, wherein said whey is selected from the group

WO 99/15024

PCT/US97/16993

- 29 -

consisting of pasteurized sweet whey, pasteurized acid whey, non-pasteurized acid whey, and whey protein concentrate.

21. The method of Claim 19, wherein said chromatographic column is a radial flow column.

22. A method for the separation of β -lactoglobulin from whey proteins, said process comprising the steps of:

- a) packing a radial flow chromatographic column with an anionic exchange resin to provide a first packed chromatographic column;
- b) equilibrating said first packed chromatographic column with a buffer;
- c) providing a whey sample containing whey proteins comprising lactoferrin, immunoglobulin, β -lactoglobulin, α -lactalbumin, and bovine serum albumin;
- d) passing said whey sample through said first packed chromatographic column under conditions wherein β -lactoglobulin adsorbs to said first packed chromatographic column and a permeate flows through said first packed chromatographic column;
- e) collecting said permeate from said first packed chromatographic column, wherein said permeate comprises α -lactalbumin, immunoglobulin, bovine serum albumin and lactoferrin suitable for further processing; and
- f) eluting said adsorbed β -lactoglobulin from said first packed chromatographic column, with a buffer to produce an eluate;
- g) packing a second chromatographic column with a cationic exchange resin to provide a second packed chromatographic column;
- h) equilibrating said second packed chromatographic column;
- i) passing said collected permeate from said first packed chromatographic column through an ultrafiltration membrane to produce an ultrafiltrate;
- k) passing said ultrafiltrate through said second packed chromatographic column, under conditions such that immunoglobulin, α -lactalbumin, bovine serum albumin, and lactoferrin adsorb to said second packed chromatographic column;
- l) eluting said immunoglobulin from said second packed chromatographic column with a buffer;

WO 99/15024

PCT/US97/16993

- 30 -

- m) reconditioning said second packed chromatographic column with a buffer;
- n) eluting said α -lactalbumin from said second packed chromatographic column with a buffer;
- o) reconditioning said second packed chromatographic column with a buffer;
- p) eluting said bovine serum albumin from said second packed chromatographic column with a buffer; and
- q) eluting said lactoferrin from said second packed chromatographic column with a buffer.

23. The method of Claim 22, wherein said permeate is combined with said eluate obtained at step f) to produce a fat substitute.
24. The method of Claim 23, wherein said fat substitute comprises about 60% said eluate and 40% said permeate.
25. The method of Claim 22, further comprising combining said α -lactalbumin, immunoglobulin, and said bovine serum albumin to produce an infant formula.
26. The method of Claim 25, wherein said infant formula further comprises at least 25% α -lactoferrin and less than one half of a percent of β -lactoglobulin.
27. The method of Claim 25, wherein said infant formula further comprises casein hydrolysate, fat, nonfat milk solids, carbohydrate, minerals, and vitamins.
28. The method of Claim 25, wherein said infant formula further comprises about 43.5% of said α -lactalbumin eluted from said second packed chromatography column at step n), about 31.6% lactoferrin eluted at step q), about 15.4% immunoglobulin eluted at step j), and about 9.5% bovine serum albumin eluted at step p).
29. An infant formula containing at least 25 percent lactoferrin and less than one half percent β -lactoglobulin.

WO 99/15024

PCT/US97/16993

- 31 -

30. An infant formula comprising α -lactalbumin, lactoferrin, immunoglobulin, and bovine serum albumin.

31. The infant formula of Claim 30, wherein said lactoferrin comprises at least 25 percent.

32. The infant formula of Claim 30, wherein said formula further comprises additives and fortifiers.

33. The infant formula of Claim 32, wherein said additives and fortifiers are selected from the group consisting of nonfat milk solids, vegetable solids, carbohydrate sweeteners, minerals, and vitamins.

34. An infant formula comprising about 43.5% α -lactalbumin, about 31.6% lactoferrin, about 15.4% immunoglobulin, and about 9.5% bovine serum albumin.

35. A fat substitute comprising about 60% β -lactoglobulin and about 40% α -lactalbumin.

36. The fat substitute of Claim 35, further comprising additives and flavor enhancers.

WO 99/15024

1/3

PCT/US97/16993




FIG. 1

WO 99/15024

2/3

PCT/US97/16993

UV trace 280 nm-20 Liter Column




FIG. 2

WO 99/15024

3/3

PCT/US97/16993




FIG. 3

ELUTION PATTERN OF WHEY PROTEINS SHOWING PEAK 4

INTERNATIONAL SEARCH REPORT

 International application No.
PCT/US97/16993

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A23C 9/14 US CL :426/271 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 426/271, 580, 656, 657 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	US 3,969,337 A (LAUER ET AL) 13 July 1976, entire document.	1-36		
Y	US 4,820,348 A (HARJU) 11 April 1989, entire document.	1-36		
Y	US 5,077,067 A (THIBAUT) 31 December 1991, entire document.	1-36		
Y	US 5,085,881 A (MOELLER) 04 February 1992, entire document.	1-36		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.				
<table border="0"> <tr> <td> * Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *B* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family </td> </tr> </table>			* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *B* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family
* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *B* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family			
Date of the actual completion of the international search 16 DECEMBER 1997		Date of mailing of the international search report 09 JAN 1998		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>Leslie Wong</i> LESLIE WONG Telephone No. (703) 308-1979		

This Page Blank (uspto)